BLZ945 is a potent and selective CSF-1R kinase inhibitor. BLZ945 showed effects of CSF1R inhibition on other tumor-infiltrating immune cells. BLZ945 attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas. BLZ945 decreases the growth of malignant cells in the mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis. BLZ945 prevents tumor progression in the keratin 14-expressing human papillomavirus type 16 (K14-HPV-16) transgenic model of cervical carcinogenesis.
Chemical Properties:
density: 1.377±0.06 g/cm3(Predicted)
pka: 13.92±0.46(Predicted)
CSF-1R Inhibitors Related Products:
GW2580; Pazopanib; Pazopanib HCl; Linifanib; ENMD-2076; ENMD-2076 Tartrate; OSI-930; Agerafenib; Ki20227; PLX5622; Pexidartinib; Pexidartinib HCL; Aprepitant; Erdafitinib